FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 344:1031-1037 April 5, 2001 Number 14 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.

Methods We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase. STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alfa had failed. Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.

Results Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea. A maximal tolerated dose was not identified. Complete hematologic responses were observed in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy. Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.

Conclusions STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed. Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.

Source Information

From the Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland (B.J.D., S.O.-J.); the Departments of Bioimmunotherapy (M.T.) and Leukemia (H.K.), University of Texas M.D. Anderson Cancer Center, Houston; the Department of Oncology Clinical Research, Novartis Pharmaceuticals, East Hanover, N.J. (D.J.R.), and Basel, Switzerland (B.P., E.B., J.M.F., N.B.L., R.C.); and the Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles (C.L.S.).

Address reprint requests to Dr. Druker at Oregon Health Sciences University, L592, 3181 SW Sam Jackson Park Rd., Portland, OR 97201, or at drukerb{at}ohsu.edu.

Full Text of this Article

This article has been cited by other articles:

• Raymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M.J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., Heinrich, M. C., Gorlia, T., Lacombe, D., van den Bent, M. J. (2008). Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. JCO 26: 4659-4665 [Abstract] [Full Text]  
• Toschi, L., Janne, P. A. (2008). Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer. Clin. Cancer Res. 14: 5941-5946 [Abstract] [Full Text]  
• Okabe, S., Tauchi, T., Ohyashiki, K. (2008). Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells. Clin. Cancer Res. 14: 6181-6186 [Abstract] [Full Text]  
• Brenner, H., Gondos, A., Pulte, D. (2008). Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. haematol 93: 1544-1549 [Abstract] [Full Text]  
• Schilsky, R. L., Gordon, G., Gilmer, T. M., Courtneidge, S. A., Matrisian, L. M., Grad, O., Nelson, W. G., on behalf of the Translational Research Working Gr, (2008). The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics). Clin. Cancer Res. 14: 5685-5691 [Abstract] [Full Text]  
• Levine, R. L., Gilliland, D. G. (2008). Myeloproliferative disorders. Blood 112: 2190-2198 [Abstract] [Full Text]  
• Chu, T. S., Chen, J. S., Lopez, J. P., Pardo, F. S., Aguilera, J., Ongkeko, W. M. (2008). Imatinib-Mediated Inactivation of Akt Regulates ABCG2 Function in Head and Neck Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg 134: 979-984 [Abstract] [Full Text]  
• Lioni, M., Noma, K., Snyder, A., Klein-Szanto, A., Diehl, J. A., Rustgi, A. K., Herlyn, M., Smalley, K. S.M. (2008). Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Molecular Cancer Therapeutics 7: 2866-2875 [Abstract] [Full Text]  
• Rothenberg, S. M., Engelman, J. A., Le, S., Riese, D. J. II, Haber, D. A., Settleman, J. (2008). Modeling oncogene addiction using RNA interference. Proc. Natl. Acad. Sci. USA 105: 12480-12484 [Abstract] [Full Text]  
• Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., Cao, L., McNally, D., Chow, C., Chen, H. X., Wright, J. J., Figg, W. D., Kohn, E. C. (2008). Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity. JCO 26: 3709-3714 [Abstract] [Full Text]  
• Smalley, K. S.M., Contractor, R., Nguyen, T. K., Xiao, M., Edwards, R., Muthusamy, V., King, A. J., Flaherty, K. T., Bosenberg, M., Herlyn, M., Nathanson, K. L. (2008). Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression. Cancer Res. 68: 5743-5752 [Abstract] [Full Text]  
• Schilder, R. J., Sill, M. W., Lee, R. B., Shaw, T. J., Senterman, M. K., Klein-Szanto, A. J., Miner, Z., Vanderhyden, B. C. (2008). Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study. JCO 26: 3418-3425 [Abstract] [Full Text]  
• de Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., Marin, D. (2008). Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis. JCO 26: 3358-3363 [Abstract] [Full Text]  
• Shah, N. P., Kantarjian, H. M., Kim, D.-W., Rea, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., Khoroshko, N., Paquette, R. L., Deininger, M., Collins, R. H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S., Hochhaus, A. (2008). Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. JCO 26: 3204-3212 [Abstract] [Full Text]  
• Perros, F., Montani, D., Dorfmuller, P., Durand-Gasselin, I., Tcherakian, C., Le Pavec, J., Mazmanian, M., Fadel, E., Mussot, S., Mercier, O., Herve, P., Emilie, D., Eddahibi, S., Simonneau, G., Souza, R., Humbert, M. (2008). Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. Am. J. Respir. Crit. Care Med. 178: 81-88 [Abstract] [Full Text]  
• Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R., Jungel, A., Zwerina, J., Gay, S., Schett, G., Distler, O., Distler, J. H. W. (2008). Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22: 2214-2222 [Abstract] [Full Text]  
• Capdeville, R., Krahnke, T., Hatfield, A., Ford, J. M., Van Hoomissen, I., Gathmann, I. (2008). Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Ann Oncol 19: 1320-1326 [Abstract] [Full Text]  
• Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., Lee, J., Richards, W. G., Sugarbaker, D. J., Ducko, C., Lindeman, N., Marcoux, J. P., Engelman, J. A., Gray, N. S., Lee, C., Meyerson, M., Janne, P. A. (2008). EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. Clin. Cancer Res. 14: 4275-4283 [Abstract] [Full Text]  
• Lobato, M. N., Metzler, M., Drynan, L., Forster, A., Pannell, R., Rabbitts, T. H. (2008). Modeling Chromosomal Translocations Using Conditional Alleles to Recapitulate Initiating Events in Human Leukemias. J Natl Cancer Inst Monogr 2008: 58-63 [Abstract] [Full Text]  
• Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., Wyhs, N., Ziaugra, L., Richter, D. J., Trovik, J., Engelsen, I. B., Stefansson, I. M., Fennell, T., Cibulskis, K., Zody, M. C., Akslen, L. A., Gabriel, S., Wong, K.-K., Sellers, W. R., Meyerson, M., Greulich, H. (2008). Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105: 8713-8717 [Abstract] [Full Text]  
• Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., Drew, L., Haber, D. A., Settleman, J. (2008). Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. Cancer Res. 68: 4853-4861 [Abstract] [Full Text]  
• Hexner, E. O., Serdikoff, C., Jan, M., Swider, C. R., Robinson, C., Yang, S., Angeles, T., Emerson, S. G., Carroll, M., Ruggeri, B., Dobrzanski, P. (2008). Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671 [Abstract] [Full Text]  
• Kavalerchik, E., Goff, D., Jamieson, C. H.M. (2008). Chronic Myeloid Leukemia Stem Cells. JCO 26: 2911-2915 [Abstract] [Full Text]  
• Loeb, L. A., Bielas, J. H., Beckman, R. A., Bodmer, I. W. (2008). Cancers Exhibit a Mutator Phenotype: Clinical Implications. Cancer Res. 68: 3551-3557 [Abstract] [Full Text]  
• Andrae, J., Gallini, R., Betsholtz, C. (2008). Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22: 1276-1312 [Abstract] [Full Text]  
• Xing, S., Wanting, T. H., Zhao, W., Ma, J., Wang, S., Xu, X., Li, Q., Fu, X., Xu, M., Zhao, Z. J. (2008). Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 111: 5109-5117 [Abstract] [Full Text]  
• Katsoulas, A., Rachid, Z., McNamee, J. P., Williams, C., Jean-Claude, B. J. (2008). Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Molecular Cancer Therapeutics 7: 1033-1043 [Abstract] [Full Text]  
• Muller, M., Obeyesekere, M., Mills, G. B., Ram, P. T. (2008). Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J. 22: 1393-1403 [Abstract] [Full Text]  
• Loriaux, M. M., Levine, R. L., Tyner, J. W., Frohling, S., Scholl, C., Stoffregen, E. P., Wernig, G., Erickson, H., Eide, C. A., Berger, R., Bernard, O. A., Griffin, J. D., Stone, R. M., Lee, B., Meyerson, M., Heinrich, M. C., Deininger, M. W., Gilliland, D. G., Druker, B. J. (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111: 4788-4796 [Abstract] [Full Text]  
• Tomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., Payton, J. E., Westervelt, P., DiPersio, J. F., Link, D. C., Walter, M. J., Graubert, T. A., Watson, M., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Bloomfield, C. D., Mardis, E. R., Wilson, R. K., Ley, T. J. (2008). Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111: 4797-4808 [Abstract] [Full Text]  
• Hodi, F. S., Friedlander, P., Corless, C. L., Heinrich, M. C., Mac Rae, S., Kruse, A., Jagannathan, J., Van den Abbeele, A. D., Velazquez, E. F., Demetri, G. D., Fisher, D. E. (2008). Major Response to Imatinib Mesylate in KIT-Mutated Melanoma. JCO 26: 2046-2051 [Full Text]  
• Weichsel, R., Dix, C., Wooldridge, L., Clement, M., Fenton-May, A., Sewell, A. K., Zezula, J., Greiner, E., Gostick, E., Price, D. A., Einsele, H., Seggewiss, R. (2008). Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib. Clin. Cancer Res. 14: 2484-2491 [Abstract] [Full Text]  
• Chou, C. J., Farkas, M. E., Tsai, S. M., Alvarez, D., Dervan, P. B., Gottesfeld, J. M. (2008). Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia. Molecular Cancer Therapeutics 7: 769-778 [Abstract] [Full Text]  
• Carayol, N., Katsoulidis, E., Sassano, A., Altman, J. K., Druker, B. J., Platanias, L. C. (2008). Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway. J. Biol. Chem. 283: 8601-8610 [Abstract] [Full Text]  
• Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K., Nakamura, H., Derdak, S., Samorapoompichit, P., Pickl, W. F., Sexl, V., Esterbauer, H., Schwarzinger, I., Sillaber, C., Maeda, H., Valent, P. (2008). Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111: 2200-2210 [Abstract] [Full Text]  
• Judson, I. R. (2008). Imatinib for Patients With Liver or Kidney Dysfunction: No Need to Modify the Dose. JCO 26: 521-522 [Full Text]  
• Ramanathan, R. K., Egorin, M. J., Takimoto, C. H.M., Remick, S. C., Doroshow, J. H., LoRusso, P. A., Mulkerin, D. L., Grem, J. L., Hamilton, A., Murgo, A. J., Potter, D. M., Belani, C. P., Hayes, M. J., Peng, B., Ivy, S. P. (2008). Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. JCO 26: 563-569 [Abstract] [Full Text]  
• Gibbons, J., Egorin, M. J., Ramanathan, R. K., Fu, P., Mulkerin, D. L., Shibata, S., Takimoto, C. H.M., Mani, S., LoRusso, P. A., Grem, J. L., Pavlick, A., Lenz, H.-J., Flick, S. M., Reynolds, S., Lagattuta, T. F., Parise, R. A., Wang, Y., Murgo, A. J., Ivy, S. P., Remick, S. C. (2008). Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. JCO 26: 570-576 [Abstract] [Full Text]  
• Contessa, J. N., Hamstra, D. A. (2008). Revoking the Privilege: Targeting HER2 in the Central Nervous System. Mol. Pharmacol. 73: 271-273 [Abstract] [Full Text]  
• Hochhaus, A., Druker, B., Sawyers, C., Guilhot, F., Schiffer, C. A., Cortes, J., Niederwieser, D. W., Gambacorti-Passerini, C., Stone, R. M., Goldman, J., Fischer, T., O'Brien, S. G., Reiffers, J. J., Mone, M., Krahnke, T., Talpaz, M., Kantarjian, H. M. (2008). Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment. Blood 111: 1039-1043 [Abstract] [Full Text]  
• Croce, C. M. (2008). Oncogenes and Cancer. NEJM 358: 502-511 [Full Text]  
• Hedley, D. W., Chow, S., Goolsby, C., Shankey, T. V. (2008). Pharmacodynamic Monitoring of Molecular-Targeted Agents in the Peripheral Blood of Leukemia Patients Using Flow Cytometry. Toxicol Pathol 36: 133-139 [Abstract] [Full Text]  
• McLaughlin, J., Cheng, D., Singer, O., Lukacs, R. U., Radu, C. G., Verma, I. M., Witte, O. N. (2007). Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc. Natl. Acad. Sci. USA 104: 20501-20506 [Abstract] [Full Text]  
• Sharma, S. V., Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21: 3214-3231 [Abstract] [Full Text]  
• Azuma, M., Nishioka, Y., Aono, Y., Inayama, M., Makino, H., Kishi, J., Shono, M., Kinoshita, K., Uehara, H., Ogushi, F., Izumi, K., Sone, S. (2007). Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice. Am. J. Respir. Crit. Care Med. 176: 1243-1250 [Abstract] [Full Text]  
• Gratwohl, A., Baldomero, H., Schwendener, A., Gratwohl, M., Apperley, J., Niederwieser, D., Frauendorfer, K., for the Joint Accreditation Committee of the Inter, (2007). Predictability of hematopoietic stem cell transplantation rates. haematol 92: 1679-1686 [Abstract] [Full Text]  
• Branford, S., Seymour, J. F., Grigg, A., Arthur, C., Rudzki, Z., Lynch, K., Hughes, T. (2007). BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria. Clin. Cancer Res. 13: 7080-7085 [Abstract] [Full Text]  
• Hoelzinger, D. B., Demuth, T., Berens, M. E. (2007). Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. JNCI J Natl Cancer Inst 99: 1583-1593 [Abstract] [Full Text]  
• Kaspers, G. J.L., Zwaan, C. M. (2007). Pediatric acute myeloid leukemia: towards high-quality cure of all patients. haematol 92: 1519-1532 [Abstract] [Full Text]  
• Agis, H., Sperr, W. R., Herndlhofer, S., Semper, H., Pirc-Danoewinata, H., Haas, O. A., Mannhalter, C., Esterbauer, H., Geissler, K., Sillaber, C., Jager, U., Valent, P. (2007). Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 18: 1834-1841 [Abstract] [Full Text]  
• Berg, S. L. (2007). Ethical Challenges in Cancer Research in Children. The Oncologist 12: 1336-1343 [Abstract] [Full Text]  
• Kebriaei, P., Detry, M. A., Giralt, S., Carrasco-Yalan, A., Anagnostopoulos, A., Couriel, D., Khouri, I. F., Anderlini, P., Hosing, C., Alousi, A., Champlin, R. E., de Lima, M. (2007). Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 110: 3456-3462 [Abstract] [Full Text]  
• Goldman, J. M. (2007). How I treat chronic myeloid leukemia in the imatinib era. Blood 110: 2828-2837 [Abstract] [Full Text]  
• White, D., Saunders, V., Grigg, A., Arthur, C., Filshie, R., Leahy, M. F., Lynch, K., To, L. B., Hughes, T. (2007). Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia. JCO 25: 4445-4451 [Abstract] [Full Text]  
• Bhargav, R., Mahapatra, M., Mishra, P., Kumar, R. (2007). Overdose with 6400 mg of imatinib: is it safe?. Ann Oncol 18: 1750-1751 [Full Text]  
• Ali, Y., Lin, Y., Gharibo, M. M., Gounder, M. K., Stein, M. N., Lagattuta, T. F., Egorin, M. J., Rubin, E. H., Poplin, E. A. (2007). Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors. Clin. Cancer Res. 13: 5876-5882 [Abstract] [Full Text]  
• Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., Chang, M., Nolan, G. P., Steinman, L., Felsher, D. W. (2007). Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood 110: 2674-2684 [Abstract] [Full Text]  
• King, M. E., Rowe, J. M. (2007). Recent Developments in Acute Myelogenous Leukemia Therapy. The Oncologist 12: 14-21 [Abstract] [Full Text]  
• Williams, R. T., den Besten, W., Sherr, C. J. (2007). Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 21: 2283-2287 [Abstract] [Full Text]  
• Lee, S. M., Bae, J. H., Kim, M. J., Lee, H. S., Lee, M. K., Chung, B. S., Kim, D. W., Kang, C. D., Kim, S. H. (2007). Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors. J. Pharmacol. Exp. Ther. 322: 1084-1092 [Abstract] [Full Text]  
• Rahmani, M., Nguyen, T. K., Dent, P., Grant, S. (2007). The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation. Mol. Pharmacol. 72: 788-795 [Abstract] [Full Text]  
• Blasdel, C., Egorin, M. J., Lagattuta, T. F., Druker, B. J., Deininger, M. W. (2007). Therapeutic drug monitoring in CML patients on imatinib. Blood 110: 1699-1701 [Full Text]  
• Frank-Raue, K., Fabel, M., Delorme, S., Haberkorn, U., Raue, F. (2007). Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157: 215-220 [Abstract] [Full Text]  
• Peng, C., Brain, J., Hu, Y., Goodrich, A., Kong, L., Grayzel, D., Pak, R., Read, M., Li, S. (2007). Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 110: 678-685 [Abstract] [Full Text]  
• Wiencke, J. K., Zheng, S., Jelluma, N., Tihan, T., Vandenberg, S., Tamguney, T., Baumber, R., Parsons, R., Lamborn, K. R., Berger, M. S., Wrensch, M. R., Haas-Kogan, D. A., Stokoe, D. (2007). Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 9: 271-279 [Abstract] [Full Text]  
• Larson, J. S. M., Bergstrom, L. K., Cameron, J. D., Erickson, L. A., Grimm, T. E. (2007). Severe Periorbital Edema Secondary to Imatinib Mesylate for Chronic Myelogenous Leukemia. Arch Ophthalmol 125: 985-986 [Full Text]  
• Kuo, Y.-Y., Chang, Z.-F. (2007). GATA-1 and Gfi-1B Interplay To Regulate Bcl-xL Transcription. Mol. Cell. Biol. 27: 4261-4272 [Abstract] [Full Text]  
• Distler, J. H W, Distler, O. (2007). Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?. Ann Rheum Dis 66: 836-836 [Full Text]  
• Nagar, B. (2007). c-Abl Tyrosine Kinase and Inhibition by the Cancer Drug Imatinib (Gleevec/STI-571). J. Nutr. 137: 1518S-1523S [Abstract] [Full Text]  
• Duncan, J. A., Bergstralh, D. T., Wang, Y., Willingham, S. B., Ye, Z., Zimmermann, A. G., Ting, J. P.-Y. (2007). Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl. Acad. Sci. USA 104: 8041-8046 [Abstract] [Full Text]  
• Jiang, X., Saw, K. M., Eaves, A., Eaves, C. (2007). Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells. JNCI J Natl Cancer Inst 99: 680-693 [Abstract] [Full Text]  
• Langley, R. R., Fidler, I. J. (2007). Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis. Endocr. Rev. 28: 297-321 [Abstract] [Full Text]  
• Nguyen, T. K., Rahmani, M., Harada, H., Dent, P., Grant, S. (2007). MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 109: 4006-4015 [Abstract] [Full Text]  
• Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.-A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., Moore, N., Molimard, M., Mahon, F.-X. (2007). Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109: 3496-3499 [Abstract] [Full Text]  
• Pollack, I. F., Jakacki, R. I., Blaney, S. M., Hancock, M. L., Kieran, M. W., Phillips, P., Kun, L. E., Friedman, H., Packer, R., Banerjee, A., Geyer, J. R., Goldman, S., Poussaint, T. Y., Krasin, M. J., Wang, Y., Hayes, M., Murgo, A., Weiner, S., Boyett, J. M. (2007). Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neuro Oncol 9: 145-160 [Abstract] [Full Text]  
• Vittal, R., Zhang, H., Han, M. K., Moore, B. B., Horowitz, J. C., Thannickal, V. J. (2007). Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases. J. Pharmacol. Exp. Ther. 321: 35-44 [Abstract] [Full Text]  
• Liu, Y., Tseng, M., Perdreau, S. A., Rossi, F., Antonescu, C., Besmer, P., Fletcher, J. A., Duensing, S., Duensing, A. (2007). Histone H2AX Is a Mediator of Gastrointestinal Stromal Tumor Cell Apoptosis following Treatment with Imatinib Mesylate. Cancer Res. 67: 2685-2692 [Abstract] [Full Text]  
• Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P. P., Palandri, F., Giannoulia, P., Marzocchi, G., Luatti, S., Testoni, N., Iacobucci, I., Cilloni, D., Saglio, G., Baccarani, M., Martinelli, G. (2007). Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. haematol 92: 401-404 [Abstract] [Full Text]  
• Breccia, M., Gentilini, F., Alimena, G. (2007). Cocaine abuse may influence the response to imatinib in CML patients. haematol 92: e41-e42 [Full Text]  
• Roberts, K. G., Odell, A. F., Byrnes, E. M., Baleato, R. M., Griffith, R., Lyons, A. B., Ashman, L. K. (2007). Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Molecular Cancer Therapeutics 6: 1159-1166 [Abstract] [Full Text]  
• Bozulic, L., Morin, P. J., Hunter, T., Hemmings, B. A. (2007). Meeting Report: Targeting the Kinome--20 Years of Tyrosine Kinase Inhibitor Research in Basel. Sci Signal 2007: pe8-pe8 [Abstract] [Full Text]  
• Sinai, P., Berg, R. E., Haynie, J. M., Egorin, M. J., Ilaria, R. L. Jr, Forman, J. (2007). Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo. J. Immunol. 178: 2028-2037 [Abstract] [Full Text]  
• Li, Z., Xu, M., Xing, S., Ho, W. T., Ishii, T., Li, Q., Fu, X., Zhao, Z. J. (2007). Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth. J. Biol. Chem. 282: 3428-3432 [Abstract] [Full Text]  
• Holtz, M., Forman, S. J., Bhatia, R. (2007). Growth Factor Stimulation Reduces Residual Quiescent Chronic Myelogenous Leukemia Progenitors Remaining after Imatinib Treatment. Cancer Res. 67: 1113-1120 [Abstract] [Full Text]  
• Diehl, K. M., Keller, E. T., Woods Ignatoski, K. M. (2007). Why should we still care about oncogenes?. Molecular Cancer Therapeutics 6: 418-427 [Abstract] [Full Text]  
• Lerma, E. I., Nguyen, V.-A., Wang, T., Tipping, A., Melo, J. V., Kufe, D., Austin, D. J., Deisseroth, A. (2007). Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Molecular Cancer Therapeutics 6: 655-666 [Abstract] [Full Text]  
• Chen, J., Yu, W.-M., Daino, H., Broxmeyer, H. E., Druker, B. J., Qu, C.-K. (2007). SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 109: 778-785 [Abstract] [Full Text]  
• Kawada, K., Murakami, K., Sato, T., Kojima, Y., Ebi, H., Mukai, H., Tahara, M., Shimokata, K., Minami, H. (2007). Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors. Jpn J Clin Oncol 37: 44-48 [Abstract] [Full Text]  
• Gallmeier, E., Kern, S. E. (2007). Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models. Clin. Cancer Res. 13: 4-10 [Abstract] [Full Text]  
• Yao, J. C., Zhang, J. X., Rashid, A., Yeung, S.-C. J., Szklaruk, J., Hess, K., Xie, K., Ellis, L., Abbruzzese, J. L., Ajani, J. A. (2007). Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors. Clin. Cancer Res. 13: 234-240 [Abstract] [Full Text]  
• Steensma, D. P., Richard, R. E. (2007). Myeloproliferative disorders. ASH-SAP 2007: 172-227 [Full Text]  
• Martinez-Gonzalez, M C., del Pozo, J., Yebra-Pimentel, M. T., Perez, M., Almagro, M., Fonseca, E. (2007). Livedoid Skin Reaction Probably Due to Imatinib Therapy. The Annals of Pharmacotherapy 41: 148-152 [Abstract] [Full Text]  
• Xu, X., Zhang, Q., Luo, J., Xing, S., Li, Q., Krantz, S. B., Fu, X., Zhao, Z. J. (2007). JAK2V617F: prevalence in a large Chinese hospital population. Blood 109: 339-342 [Abstract] [Full Text]  
• Kantarjian, H. M., Talpaz, M., Giles, F., O'Brien, S., Cortes, J. (2006). New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance. ANN INTERN MED 145: 913-923 [Abstract] [Full Text]  
• Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., Radaelli, F., Ciccone, F., Tiribelli, M., di Lorenzo, R., Caracciolo, C., Izzo, B., Pane, F., Saglio, G., Baccarani, M., Martinelli, G., on behalf of the GIMEMA Working Party on Chronic M, (2006). Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12: 7374-7379 [Abstract] [Full Text]  
• Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W.N., Silver, R. T., Goldman, J. M., Stone, R. M., Cervantes, F., Hochhaus, A., Powell, B. L., Gabrilove, J. L., Rousselot, P., Reiffers, J., Cornelissen, J. J., Hughes, T., Agis, H., Fischer, T., Verhoef, G., Shepherd, J., Saglio, G., Gratwohl, A., Nielsen, J. L., Radich, J. P., Simonsson, B., Taylor, K., Baccarani, M., So, C., Letvak, L., Larson, R. A., the IRIS Investigators, (2006). Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. NEJM 355: 2408-2417 [Abstract] [Full Text]